Item 8.01. Other Events.
On January 21, 2020, BeiGene, Ltd. (the "Company") announced that the pivotal
Phase 3 trial evaluating its anti-PD-1 antibody tislelizumab in combination with
two chemotherapy regimens for the first-line treatment of patients with squamous
non-small cell lung cancer (NSCLC), met the primary endpoint of improved
progression-free survival (PFS) at the planned interim analysis, as assessed by
independent review committee (IRC). A copy of the press release is filed as
Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference
herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release issued by the Company on January 21, 2020
The cover page from this Current Report on Form 8-K, formatted in
104 Inline XBRL
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses